Fundamental basis for rational therapeutics in acute otitis media

Pediatric Infectious Disease Journal

Volumn 18, Issue 12, 1999, Pages 1130-1140

  Blumer, Jeffrey L ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IntraMed   (United States)

Author keywords

Antimicrobial therapy; Beta lactams; Macrolides; Otitis media; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DRUG METABOLITE; ERYTHROMYCIN; LORACARBEF; MACROLIDE; OFLOXACIN; PEDIAZOLE; PENICILLIN DERIVATIVE; THEOPHYLLINE;

ANTIMICROBIAL ACTIVITY; CHEMOTHERAPY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MORAXELLA CATARRHALIS; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0032761080     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199912000-00028     Document Type: Review

References (49)

1. Teele DW, Klein JO, Rosner B, et al. Epidemiology of otitis media during the first seven years of life in children in Greater Boston: a prospective, cohort study. J Infect Dis 1989;160:83-93.
2. Bluestone CD, Stephenson JS, Martin LM. Ten year review of otitis media pathogens. Pediatr Infect Dis J 1992;11:S7-11.
3. Green SM, Rothrock SG. Single-dose intramuscular ceftriax-one for acute otitis media in children. Pediatrics 1993;91:23-30.
4. Uhari M, Mantysaari K, Neimela M. A meta-analytic review of the risk factors for acute otitis media. Clin Infect Dis 1996;22:1079-83.
5. Alho OP, Laara E, Oja H. How should relative risk estimates for acute otitis media in children aged less than 2 years be perceived? J Clin Epidemiol 1996;49:9-14.
6. Drug-resistant Streptococcus pneumoniae: Kentucky and Tennessee, 1993. MMWR 1994;43:23-6.
7. Klein JO. Otitis media. Clin Infect Dis 1994;19:823-33.
8. Dowell SF, Marcy SM, Phillips WR, Gerber MA, Schwartz B. Otitis media: principles of judicious use of antimicrobial agents. Pediatrics 1998;101(Suppl):165-71.
9. Bluestone CD, Klein JO. Microbiology. In: Otitis media in infants and children. 2nd ed. Philadelphia: Saunders, 1995: 55-72.
10. Bluestone CD, Klein JO. Complications and sequelae: intratemporal. In: Otitis media in infants and children. 2nd ed. Philadelphia: Saunders, 1995:241-303.
11. Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 1997;16:449-56.
12. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-82.
13. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5.
14. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: meta-analysis from thirty-three randomized trials. J Pediatr 1994;124:355-67.
15. Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am 1995;42:509-17.
16. McCracken GH. Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J 1995; 14:424-8.
17. Blumer JL. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr Infect Dis J 1998;17:1070-5.
18. Blumer JL. Implications of pharmacokinetics in making choices for the management of acute otitis media. Pediatr Infect Dis J 1998;17:565-70.
19. Khurana CM. Issues concerning antibiotic use in child care settings. Pediatr Infect Dis J 1995;14(Suppl):S34-8.
20. Nies AS, Spielberg SP. Principles of therapeutics. In: Gilman AG, consulting ed.; Hardman JG, Limbird LE, eds-in-chief; Molinoff PB, Ruddon RW, eds. Goodman & Gilman's The pharmacologic basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:43-62.
21. Salyers AA, Amabile-Cuevas CF. Why are antibiotic resistance genes so resistant to elimination? Antimicrob Agents Chemother 1997;41:2321-5.
22. Jones RN, Jacobs MR, Washington JA, Pfaller MA. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents: a 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis 1997;27:75-83.
23. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40: 1208-13.
24. Washington JA. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994: the Alexander Project. Diagn Microbiol Infect Dis 1996;25:183-90.
25. Wise R, Andrews JM, Ashby JP, Thornber D. Ceftibuten: in vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action. J Antimicrob Chemother 1990;26:209-13.
26. Gudnason T, Gudbrandsson F, Barsante F, Kristinason KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J 1998;17:258-60.
27. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992;26:46-55.
28. Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am 1995;79:803-15.
29. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996;15(Suppl):S30-7.
30. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993;31(Suppl C):1-9.
31. Menninger JR. Functional consequences of binding macrolides to ribosomes. J Antimicrob Chemother 1985;16(Suppl A):23-34.
32. Reed MD, Blumer JL. Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice. Pediatr Infect Dis J 1997;16:1069-83.
33. Bauernfeind A. In vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother 1993;31(Suppl C):39-49.
34. Zuckerman JM, Kaye KM. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am 1995;9:731-45.
35. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
36. Rosenfeld RM. What to expect from medical treatment of otitis media. Pediatr Infect Dis J 1995;14:731-8.
37. Pichichero ME, Pichichero CL. Persistent acute otitis media: I. Causative pathogens. Pediatr Infect Dis J 1995;14:178-83.
38. Pichichero ME, Pichichero CL. Persistent acute otitis media: II. Antimicrobial treatment. Pediatr Infect Dis J 1995;14: 183-8.
39. Pichichero ME. Therapeutic considerations for management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 1992;6:167-74.
40. Pichichero ME, McLinn S, Aronovitz G, et al. Cefprozil treatment of persistent and recurrent acute otitis media. Pediatr Infect Dis J 1997;16:471-8.
41. Dagan R, Phillip M, Watemberg NM, Kassis I. Outpatient treatment of serious community-acquired pediatric infections using once daily intramuscular ceftriaxone. Pediatr Infect Dis J 1987;6:1080-4.
42. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microb Infect Dis 1995;22:89-96.
43. Barnett ED, Teele DW, Klein JO, et al. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media. Pediatrics 1997;99:23-8.
44. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15: 255-9.
45. Harrison CJ. Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy. Pediatr Infect Dis J 1997;16(Suppl):S12-16.
46. Camafax DM, Yan Z, Chonmartree T, Deka K, Rusilie HQ, Giebink GS. Amoxicillin middle ear fluid penetration in children with acute otitis media. Pediatr Infect Dis J 1998; 17:149-56.
47. van Buchem FL, Dunk JHM, van't Hof MA. Therapy of acute otitis media: myringotomy, antibiotics or neither? A double-blind study in children. Lancet 1981;2:883-7.
48. van Buchem FL, Peeters MF, van't Hof MA. Acute otitis media: a new treatment strategy. Br Med J (Clin Res) 1985;290:1033-7.
49. Froom J, Culpepper L, Jacobs M, et al. Antimicrobials for acute otitis media? A review from the International Primary Care Network. Br Med J 1997;315:98-102.